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the reliability of the anchor and the estimated MID. METHODS: We performed a 
simulation study in which the reliability of the anchor used for MID estimation was 
varied systematically. Features of real-life data (e.g., skewed distribution, discreteness 
of PRO scale) and anchors were used to generate simulated PRO scales and anchors. 
MIDs were then estimated on the basis of the simulated data. RESULTS: Compared 
to the MID value obtained with an anchor with perfect reliability (r = 1), a marked 
attenuation of the MID was observed when reducing the reliability of the anchor. 
Thus, an anchor with reliability 0.7 gave rise to a 24% to 35% decrease of the MID 
estimate and an anchor with reliability 0.5 led to a 45% to 55% reduction. Based on 
the ﬁ ndings and on theoretical considerations, we suggest a method for bias correction. 
CONCLUSIONS: When determining the MID of a PRO scale by an anchor-based 
method, the reliability of the anchor plays a crucial role. Anchors with poor to moder-
ate reliability may lead to considerable underestimation of the MID. Bias correction 
is possible provided the reliability of the anchor is known. 
PODIUM SESSION III: PRICING AND MARKET ACCESS
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OBJECTIVES: Value-based pricing has recently been discussed by international orga-
nizations as a means to estimate a drug price that is linked to the beneﬁ ts it offers 
patients and society. However, one of the challenges with value-based pricing is 
determining the optimal threshold for health policy decision-making. The World 
Health Organization (WHO) has recommended using multiples of a country’s per 
capita GDP as the value threshold. In this study, pharmacoeconomic modeling was 
used to estimate a value-based monthly price for a hypothetical new cancer drug that 
provides a 3-month survival to patients with metastatic colorectal cancer (mCRC). 
METHODS: A decision model was developed to simulate progression free and overall 
survival in mCRC patients receiving standard chemotherapy ± the new drug. Out-
comes for cancer control and side effects were abstracted from randomized trials in 
mCRC. Costs for chemotherapy were obtained from Canadian cancer centers. Utility 
estimates measured as quality-adjusted life-years (QALYs) were determined by inter-
viewing 24 oncology nurses and pharmacists using the Time Trade-Off technique. The 
monthly price of the new drug was then modeled using a threshold of $117,000 per 
QALY gained, which is three times the Canadian per capita GDP, as recommended 
by the WHO. RESULTS: The analysis suggested that a monthly price of $2180 would 
be considered cost-effective from the Canadian public health perspective. If the drug 
were able to improve patient quality of life or survival from 3 to 6 months, the monthly 
price could increase to $4100 and $3430 and offer the same value. CONCLUSIONS: 
The use of the WHO criteria for estimating a value-based price is feasible. However, 
one of the challenges would be to identify an appropriate threshold that would provide 
a balance between what governments can afford to pay and the commercial viability 
of the product in the reference country.
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OBJECTIVES: Many countries are adapting their pharmaceutical reimbursement 
system, increasingly emphasizing the role of pharmacoeconomics in decision-making. 
The aim of our study is to analyze European regulatory systems to obtain insight into 
best practice systems that deliver value for money. METHODS: The analytical Hutton 
Framework was used for comparing and assessing “fourth hurdle” drug reimburse-
ment systems in the The Netherlands, Belgium, Sweden, and France. We investigated 
policy documents, explored literature, and conducted interviews with policymakers 
and representatives of the pharmaceutical industry. RESULTS: All systems have a 
centralized decision body, even though the ﬁ nancial responsibility may be regional 
(Sweden). Only in Sweden, the minister has no role at the individual reimbursement 
decision level. None of the systems has a fully independent evaluation process and the 
impact of the systems is mainly assessed on drug expenditure. All countries make 
efforts to increase transparency. However, in Sweden manufacturers may withdraw 
their application before the ﬁ nal reimbursement decision, guaranteeing conﬁ dentiality 
at the cost of less transparency. Policies to deal with uncertainty vary per country: 
ﬁ nancial risk-sharing agreements by price/volume contracts—France—versus out-
comes-based agreements for expensive inpatient drugs—the The Netherlands. The 
actual value of a drug and disease severity is reﬂ ected in the level of reimbursement 
in France and Belgium, whereas in the The Netherlands and Sweden, enlisted drugs 
are fully reimbursed. All countries attempt to increase the importance of pharmaco-
economics in decision-making. However, no country expresses the relative importance 
of cost-effectiveness compared to other criteria nor applies a strictly deﬁ ned threshold. 
CONCLUSIONS: This study reveals that while there is a convergence in scientiﬁ c 
evaluation processes, important differences remain between the Dutch, Belgian, 
Swedish, and French regulatory frameworks. All countries recognize that pharmaco-
economics has a place in decision-making on value for money, but for the time being, 
pharmacoeconomics seems to play a rather undeﬁ ned role.
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OBJECTIVES: Finnish retail prices for drugs are determined with a pricing scheme 
(PS). The PS is of the form “multiplier × wholesale price + ﬁ xed sum.” The multiplier 
ranges from 1.125 to 1.5 (being smaller for higher wholesale prices), whereas the ﬁ xed 
sum ranges from 0.5 to 47.68 euros (being larger for higher wholesale prices). 
Although PS is regressive, it nevertheless provides higher absolute pharmacy margins 
for drugs with higher wholesale prices. At the lower end of wholesale prices, PS results 
in retail prices that do not cover dispensing costs. Despite this, the retail prices (exclud-
ing VAT 8%) are used to represent all drug and drug delivery costs in economic evalu-
ations. This study assesses the impact of this Finnish system-derived “distortion” in 
cost-effectiveness analyses. METHODS: The cost utilities of new hypothetical treat-
ments were assessed in a setting where the new and old treatments produce different 
amounts of quality-adjusted life-years (QALYs) and the only cost difference comes 
from the pharmaceutical prices. The treatments are assumed not to differ regarding 
the real costs of drug delivery and patient survival. The PS-induced computational 
cost difference was deducted from the retail price differences of new and old treatments 
to estimate the impact of PS on the incremental cost-effectiveness ratios (ICER). 
RESULTS: The computational cost differences due to PS ranged from 7.3 to 1 951 
euros and the QALYs gained ranged from 0.004 to 0.070 in estimated scenarios. The 
respective ICERs increased by 104 to 487 840 euros/QALY due to the PS. CONCLU-
SIONS: The PS signiﬁ cantly worsens the ICERs obtained for more expensive and often 
innovative pharmaceuticals. The Finnish PS is problematic when the aim is to provide 
optimal, cost-effective treatments to Finnish patients. In the current form, the PS 
discourages innovation and may prevent reimbursement of otherwise cost-effective 
treatments.
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OBJECTIVES: To develop a framework for integrating pricing and reimbursement 
with health economics and outcomes research and health policy to achieve commer-
cially desirable prices and levels of access in 2010 and beyond. METHODS: A review 
of recent pricing policy and regulatory changes of countries, especially those in the 
ﬁ nancially troubled Eurozone, was conducted. This was supplemented by a review of 
P&R decisions for a selection of drug launches between 2005 and 2009 and catego-
rized according to the level of therapeutic innovation and disease type (conventional, 
rare diseases, oncology). a search was performed on the OHE and NHS EED databases 
and HTA reports to establish the level of published value evidence in support of these 
launches, and ﬁ nally, the components of most importance to a market access strategy 
were identiﬁ ed and validated through interviews across different stakeholder types. 
RESULTS: The review identiﬁ ed since January 2010, there have been 11 pricing policy 
and regulatory changes. From the review of recent P&R decisions and stakeholder 
interviews, the main components identiﬁ ed were: competitive and environmental 
analysis (market assessment, reimbursement, revenue forecasts, policy trends); analysis 
of payer’s decision drivers (payer, physician, and other stakeholder qualitative 
research); value demonstration (value hypotheses, economic modeling, patient-
reported outcomes, scientiﬁ c advice); pricing strategy (price targets, cross-market 
revenue optimization modeling, country launch sequencing, scenario planning); and 
local market access tactics (HTA, risk sharing, contracting negotiations with payers). 
The review of the P&R decisions also demonstrated an increasing trend toward 
deployment of risk-sharing schemes since 2008. CONCLUSIONS: Development of a 
successful market access strategy requires an understanding of pricing, health econom-
ics and outcomes research, health technology assessment (HTA), and health policy, 
and continually keeping vigilant and adapting to rapid changes in the policy environ-
ment. This research gives direction to health economics, P&R, and government affairs 
professionals for the development of an integrated framework for the design and 
implementation of a global market access strategy. 
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BACKGROUND: In literature, economic models of ﬂ u vaccination in elderly (65+) 
most often consider the target population as one homogeneous age group evaluated 
during a 1-year time period (= 1-year 65+ group cohort model). Because the mortality 
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rates in elderly steeply increase with age and the transition probabilities for speciﬁ c 
health states are age speciﬁ c, this population should be evaluated as non-homogeneous 
and over a lifetime with annual vaccinations. This study compares the cost results of 
ﬂ u vaccination between these two different modeling approaches. METHODS: Two 
models were developed to estimate the direct costs of annual ﬂ u vaccination compared 
with no vaccination: 1) a 1-year 65+ group cohort model; and 2) a lifetime multi-age 
cohort model with target population and clinical pathways stratiﬁ ed in ﬁ ve age cohorts 
(65–69 years; 70–74 years; 75–79 years; 80–84 years; 85+ years) eligible for annual 
vaccination. Both models were populated with US speciﬁ c data. Vaccination coverage 
and disease management were identical in both models. The decision tree included the 
following states: natural deaths, infected, and symptomatic states followed by GP 
visits, hospitalizations (pneumonia, inﬂ uenza, stroke, myocardial infarction, and con-
gestive heart failure), disease-speciﬁ c death rates, and recovery in nursing homes. 
Undiscounted costs per individual per year are compared for vaccinated and unvac-
cinated groups, using both approaches. RESULTS: The cost per individual per year 
is higher in the 1-year 65+ group cohort model versus the lifetime multi-age cohort 
model (no vaccination: $205 vs. $139; vaccination: $185 vs. $113) as expected: 
considering additional age cohorts with decreasing life expectancies in the multi-age 
cohort lowers the average cost per individual per year. Meanwhile, the selection of 
model type impacts the estimated incremental cost of vaccinated versus unvaccinated 
groups ($−20 vs. $−26). CONCLUSIONS: In economic assessments, a 1-year 65+ 
group cohort approach undervalues the impact of heterogeneity in elderly on the 
beneﬁ t of ﬂ u vaccination, and therefore, a lifetime multi-age cohort is preferred.
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OBJECTIVES: Several dynamic approaches can simulate epidemics and vaccination 
strategies. Generally, the models can be divided into top-down approaches like 
Markov models and differential equations and bottom-up approaches like cellular 
automata and agent-based models. Top-down approaches are characterized by cumu-
lative values that are representing groups of people. Bottom-up approaches, in con-
trast, consider individuals. Both approaches have advantages and disadvantages. 
Top-down approaches can be analyzed very well with mathematical methods, while 
bottom-up approaches require comparison of the outcome of simulation runs with 
different parameter sets. To improve validity of model structures, a method that 
compares different approaches for epidemic models is introduced. METHODS: Sta-
tistical calculations and Markov models are static, while other approaches like dif-
ferential equations or individual-based models are dynamic. In this context, dynamic 
does not only stand for simulation over time but also for models where the calculation 
of the next time step or period depends on the current state of the model. Since the 
transition matrices in Markov models are calculated before execution time, it is not 
considered to be dynamic. The advantage of dynamic models is that they can produce 
highly nonlinear behavior that cannot be reached with static calculations. To validate 
the structure of such nonlinear models, different model types are implemented and 
compared. Results are compared; sensitivity analysis is done separately. RESULTS: 
Outcome of vaccination against streptococcus pneumoniae was tested. a differential 
equations model and an agent-based model could reproduce results of published 
Markov models. As soon as we consider population dynamics, herd immunity, and 
serotype replacement, the Markov model was not able to fulﬁ ll the structural require-
ments anymore, while dynamic approaches still work. CONCLUSIONS: Dynamic 
models offer more information and opportunities for epidemic simulation. Usage of 
different approaches provides at least comparable reliability.
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OBJECTIVES: The aim of the current study was to determine inﬂ uenza vaccination 
rates among high- and non-high-risk adults across Europe (UK, France, Germany, 
Italy, and Spain). METHODS: Data from the 2008 EU National Health and Wellness 
Survey (NHWS) were used. Demographics, comorbidities, and vaccination behavior 
in the past year were assessed for all respondents. Health-related quality of life (SF-
12v2) and resource use (number of emergency room visits, hospitalizations, and physi-
cian visits) in the past 6 months were also measured. RESULTS: Only 23.7% of 
respondents received an inﬂ uenza vaccine in the past year (UK: 25.3%, Germany: 
25.2%, France: 20.2%, Italy: 24.8%, Spain: 24.1%). a total of 28,158 respondents 
(52.6%) were at high risk for inﬂ uenza complications (i.e., over age 50, had chronic 
conditions such as asthma, diabetes, COPD, cardiovascular conditions, or HIV/AIDS). 
Those at high risk reported signiﬁ cantly lower levels of both physical quality of life 
(mean = 45.88 vs. mean = 52.10) and health utilities (mean = 0.72 vs. mean = 0.73), 
and signiﬁ cantly higher levels of emergency room visits (mean = 0.21 vs. mean = 0.17), 
hospitalizations (mean = 0.22 vs. mean = 0.12), and provider visits (mean = 5.96 vs. 
mean = 4.14) in the past 6 months relative to those not at high risk, all P < 0.0001. 
Despite the signiﬁ cantly worse health proﬁ le, only 35.9% of high-risk respondents 
received the vaccine. High-risk status was the strongest driver of vaccination in the 
UK (high risk: 42.2% vaccinated vs. non-high risk: 5.4% vaccinated, Φ = 0.42) and 
the weakest in Germany (high risk: 31.8% vaccinated vs. non-high risk: 16.2% vac-
cinated, Φ = 0.18). The most common reason for nonvaccination was a belief that the 
vaccine was unimportant (35.9%). CONCLUSIONS: Despite inﬂ uenza vaccine rec-
ommendation guidelines, only a modest percentage of respondents in Europe were 
vaccinated. Even those at high risk for inﬂ uenza complications, who reported signiﬁ -
cantly worse health outcomes than non-high-risk respondents, were vaccinated at less 
than a 40% rate.
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OBJECTIVES: To perform a cost-effectiveness analysis of newborn universal vaccina-
tion against hepatitis B virus (HBV) and to identify the cost-effective affordability 
levels of the vaccination program in Vietnam. METHODS: We simulated a birth 
cohort using 1,693,000 newborns in 2002. Incremental cost-effective ratios (ICERs) 
per quality-adjusted-life-year (QALY) gained with universal newborn vaccination 
against HBV was calculated using a Markov model. Two types of analyses (including 
and excluding expenditure on the treatment of chronic hepatitis B and its complica-
tions) were performed. We used 5000 Monte Carlo simulations to examine the cost-
effectiveness acceptability and affordability of the vaccination program from the 
payer’s perspective and to derive a cost-effective affordability curve to assess the 
program’s cost and health effects. All costs were expressed in 2002 US dollars. 
RESULTS: In the base-case scenario, newborn universal vaccination against HBV 
reduced the carrier rate by 58% at a cost of US$42 per carrier averted. From the 
payer’s perspective, marginal cost per life-year and per QALY gained were US$4.76, 
much lower than GDP per capita of ~US$440 in 2002. The vaccination could be 
potentially affordable starting at a relatively low budget of US$1.7 million. Newborn 
universal vaccination would save US$ 1 billion from the treatment cost of complica-
tions due to chronic HBV infections. The probability of vaccination being both cost-
effective and affordable is 27% at an annual budget of US$4.1 million at the 
cost-effectiveness threshold of US$3.9 per QALY. CONCLUSIONS: Universal 
newborn vaccination against HBV is highly cost-effective in Vietnam. In low-income, 
high-endemic countries, where funds are limited and economic results of vaccination 
are uncertain, our ﬁ ndings on the cost-effectiveness affordability options would assist 
decision-makers in making proper health investments in vaccination strategies against 
HBV. 
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OBJECTIVES: Platinum-based chemotherapy is a common ﬁ rst-line treatment of 
NSCLC; tolerability impacts on choice of regimen. This research compared the toler-
ability of geﬁ tinib and doublet chemotherapy in this setting in patients with activating 
epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutations (M+). 
METHODS: Systematic searching of CENTRAL, EMBASE, and MEDLINE for ran-
domized controlled trials (RCTs) comparing ≥2 doublet chemotherapies (carboplatin 
or cisplatin in combination with either docetaxel, gemcitabine, paclitaxel, pemetrexed, 
or vinorelbine) for the ﬁ rst-line treatment of advanced NSCLC was completed in May 
2009. Data were extracted on the following grades 3/4/5 adverse events (AEs) most 
commonly reported with doublet chemotherapy or EGFR-TK inhibitors: anemia, 
diarrhea, fatigue, febrile neutropenia, nausea/vomiting, neutropenia, and rash. We 
performed a meta-analysis of the available geﬁ tinib versus paclitaxel/carboplatin RCTs 
in EGFR-TK M+ patients. We then carried out a mixed treatment comparison (MTC) 
of doublet chemotherapies in unselected advanced NSCLC patients using paclitaxel/
carboplatin as a baseline. Treatment effect for the risk of AE occurrence was estimated 
as an odds ratio (OR > 1.0 favors paclitaxel/carboplatin). RESULTS: Three RCTs were 
identiﬁ ed for geﬁ tinib, of which two were comparisons with paclitaxel/carboplatin. Meta-
analysis of these two trials gave the following statistically signiﬁ cant results: anemia—OR 
0.12, 95% conﬁ dence interval: 0.03–0.47; diarrhea—OR 5.78, 95% CI: 1.01–33.11; 
neutropenia—OR 0.01, 95% CI: 0.00–0.03. Twenty-nine trials were appropriate for 
inclusion in the MTC. The alternative doublet chemotherapy regimens did not demon-
strate a statistically signiﬁ cant reduction in risk of any of the AEs assessed versus paclitaxel/
carboplatin, with the exception of gemcitabine/cisplatin, which had a lower risk of febrile 
neutropenia (OR 0.39, 95% credible interval: 0.12–0.96). CONCLUSIONS: In the 
absence of RCTs comparing all doublet chemotherapies with geﬁ tinib in EGFR-TK 
M+ patients with advanced NSCLC, this adjusted indirect comparison suggests that 
geﬁ tinib may have important tolerability advantages over other ﬁ rst-line treatments 
in this targeted population.
